多数全关节置换术患者在出院时华法林抗凝未达治疗水平:避免使用华法林作为静脉血栓栓塞预防的又一理由?
该回顾性研究分析了2011至2016年2927例初次全关节置换术后接受华法林预防静脉血栓栓塞的患者,发现出院时93.9%的患者INR低于治疗水平(<2.0),平均INR为1.41,平均住院2.53天;抗凝管理服务参与64.9%患者的术后华法林给药,参与组出院时未达治疗水平的可能性较低,但INR绝对差异可能无临床意义。
要点
- 出院时93.9%的患者INR未达治疗水平(INR<2.0),平均INR为1.41。
- 抗凝管理服务管理64.9%患者的术后华法林给药,其管理组出院时未达治疗水平的可能性较低。
- 共发生19例静脉血栓栓塞,其中13例延长住院以达到治疗水平INR。
核心结论
- 尽管有抗凝管理服务管理,多数患者出院时INR仍低于治疗水平。
- 患者出院时华法林抗凝可能不充分,引发显著的患者安全关切及医疗法律影响。
研究设计与样本
- 回顾性综述,纳入2011至2016年2927例接受华法林作为术后静脉血栓栓塞化学预防的初次全关节置换术患者。
- 通过电子病历查询确定抗凝管理服务参与、住院时长、出院时INR及院内并发症。
- INR分类为:未达治疗水平(INR<2.0)、治疗水平(2.0≤INR<3.0)、超治疗水平(INR≥3.0)。
- 采用描述性统计、卡方检验和t检验进行分析。
主要发现
- 出院时93.9%的患者INR未达治疗水平,平均INR为1.41,平均住院时长为2.53天。
- 与未达治疗水平相关的因素包括男性、较短住院时长、较少合并症、较少院内并发症及较高体重指数。
- 抗凝管理服务监督了64.9%患者的术后华法林给药;与无抗凝管理服务参与的患者相比,抗凝管理服务管理组出院时未达治疗水平的可能性较低,但INR绝对差异可能无临床意义。
- 共发生19例静脉血栓栓塞,其中13例延长住院以达到治疗水平INR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Warfarin has been used as prophylaxis against venous thromboembolism (VTE) after total joint arthroplasty (TJA) for over 60 years. With trends of shorter hospital stays for TJA patients, it is important to examine how many patients achieve therapeutic international normalized ratio (INR) at time of discharge. We aimed at elucidating the proportion of patients discharged at therapeutic INR and whether this is affected by inpatient specialty anticoagulation management service (AMS) involvement. METHODS: We conducted a retrospective review of 2927 primary TJA patients who received warfarin as postoperative VTE chemoprophylaxis from 2011 to 2016. An electronic chart query determined AMS input, length of stay (LOS), INR at discharge, and in-hospital complications. INR results were categorized as subtherapeutic (INR < 2.0), therapeutic (2.0 ≤ INR < 3.0), and supratherapeutic (INR ≥ 3.0). Descriptive statistics, chi-square, and t-tests were performed for analysis. RESULTS: At discharge, 93.9% of patients had subtherapeutic INR. Average INR was 1.41 with average LOS of 2.53 days. Factors associated with being subtherapeutic included male gender, shorter LOS, fewer comorbidities, reduced in-hospital complications, and higher body mass index. AMS supervised postoperative warfarin dosing in 64.9% of patients. Patients managed by AMS were less likely to be subtherapeutic at discharge compared to those without AMS input; however, the absolute difference in INR may not be clinically significant. There were 19 VTEs, of which 13 had prolonged hospitalization to achieve therapeutic INR. CONCLUSION: The majority of patients are discharged at subtherapeutic INR levels despite management by AMS. Patients may not be adequately anticoagulated with warfarin at time of discharge, raising significant patient safety concerns as well as medicolegal implications.
引用
- Rondon AJ, Goswami K, Tan TL, et al. Majority of Total Joint Arthroplasties Are Subtherapeutic on Warfarin at Time of Discharge: Another Reason to Avoid Warfarin as a Venous Thromboembolism Prophylaxis? J Arthroplasty. 2018. PMID: 29871833. doi:10.1016/j.arth.2018.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。